ClinicalTrialsFinder

Resectable Biliary Tract Cancer Clinical Trials in Seoul

1 recruitingSeoul, South Korea

Showing 1–1 of 1 trials

Recruiting
Phase 1Phase 2

First-line Trastuzumab, Gemcitabine, Cisplatin and Nivolumab in Advanced HER2- Positive Biliary Tract Cancer: a Multicenter, Open-label, Single-arm Phase Ib/II Trial (HERBOT)

HER2 Positive Advanced/Metastatic/Nonresectable Biliary Tract Cancer
Yonsei University44 enrolled1 locationNCT05749900